Lv4
440 积分 2024-09-04 加入
The beneficial effects of modest weight loss on cardiovascular risk factors
3天前
求助中
Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes
1个月前
已完结
The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy
2个月前
已完结
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
2个月前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
2个月前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
2个月前
已完结
Atrasentan in Patients with IgA Nephropathy
2个月前
已完结
Association of weight status and the risks of diabetes in adults: a systematic review and meta-analysis of prospective cohort studies
2个月前
已完结
Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)
3个月前
已完结
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
3个月前
已完结
皖公网安备34019202002308
